No Data
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Acurx Pharmaceuticals (ACXP), ARS Pharmaceuticals (SPRY) and Demant (OtherWILLF)
ARS Pharmaceuticals' Q1 Net Loss Widens, Revenue Tops Estimates
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Net Loss $0.35 a Share, Vs. FactSet Est of $0.32 Loss
ARS Pharmaceuticals | 10-Q: Quarterly report
Express News | ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of Neffy® (Epinephrine Nasal Spray)
Gen Xeno Trades : Which of these were day trades?
Swami : Nice!!!
Christopher Cioc : good lord
I wish I had money to play like that! I'm happy I finally ended my losing streak before I lost all my play money!